Patients treated with mitapivat showed decreases in both sTfR and erythroferrone, increases in hepcidin, and improvements in LIC from baseline, with improvements in LIC particularly marked in the subgroup of patients with iron overload at baseline. This evidence concerns the gene HAMP and Tangier disease.